HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
Anita Y M KwanUlagamadesan VenkatesanJan BasileDenis XavierJuan M MaldonadoSohini RahaManige KonigPublished in: Diabetes care (2022)
Dulaglutide 1.5-mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.
Keyphrases
- type diabetes
- cardiovascular disease
- newly diagnosed
- end stage renal disease
- body mass index
- ejection fraction
- glycemic control
- clinical trial
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- study protocol
- patient reported outcomes
- skeletal muscle
- phase ii
- combination therapy
- open label
- weight loss